On December 17, 2020, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the Regeneron antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19 (https://www.nejm.org/doi/full/10.1056/NEJMoa2035002). "The peer-reviewed NEJM publication of our first set of clinical data in recently infected COVID-19 patients showed that casirivimab and imdevimab effectively reduced viral load and the need for medically-attended visits, with the greatest benefit in patients who had not yet mounted their own effective immune response or had high viral load at baseline," said David Weinreich, MD, Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. "The investigational cocktail is now available to indicated high-risk U.S. patients under an Emergency Use Authorization, and we also continue a robust clinical development program." "Building on these initial findings, we were gratified to recently report follow-on data from the next-stage analysis of this ongoing trial, which prospectively replicated these results in a rigorous and statistically significant manner. These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention," said George D. Yancopoulos, MD, PhD, President and Chief Scientific Officer at Regeneron.
Login Or Register To Read Full Story